药物研发面临危机。
Drug discovery in jeopardy.
作者信息
Cuatrecasas Pedro
机构信息
Department of Pharmacology, University of California San Diego, San Diego, California 92067, USA.
出版信息
J Clin Invest. 2006 Nov;116(11):2837-42. doi: 10.1172/JCI29999.
Abstract
Despite striking advances in the biomedical sciences, the flow of new drugs has slowed to a trickle, impairing therapeutic advances as well as the commercial success of drug companies. Reduced productivity in the drug industry is caused mainly by corporate policies that discourage innovation. This is compounded by various consequences of mega-mergers, the obsession for blockbuster drugs, the shift of control of research from scientists to marketers, the need for fast sales growth, and the discontinuation of development compounds for nontechnical reasons. Lessons from the past indicate that these problems can be overcome, and herein, new and improved directions for drug discovery are suggested.
摘要
尽管生物医学科学取得了显著进展，但新药的研发速度已放缓至涓涓细流，这不仅阻碍了治疗方面的进步，也影响了制药公司的商业成功。制药行业生产力下降主要是由抑制创新的公司政策导致的。大型合并的各种后果、对重磅炸弹药物的痴迷、研究控制权从科学家向营销人员的转移、对快速销售增长的需求以及因非技术原因停止开发化合物等因素，使情况更加复杂。过去的经验表明，这些问题是可以克服的，本文提出了药物研发新的改进方向。
相似文献
1
Drug discovery in jeopardy.药物研发面临危机。
J Clin Invest. 2006 Nov;116(11):2837-42. doi: 10.1172/JCI29999.
2
Are we living in the end of the blockbuster drug era?我们正生活在重磅炸弹药物时代的末期吗？
Drug News Perspect. 2010 Dec;23(10):670-84. doi: 10.1358/dnp.2010.23.10.1506088.
3
Lessons from 60 years of pharmaceutical innovation.60年药物创新的经验教训。
Nat Rev Drug Discov. 2009 Dec;8(12):959-68. doi: 10.1038/nrd2961.
4
Discovery of veterinary antiparasitic agents in the 21st century: a view from industry.21 世纪兽医驱虫剂的发现：来自工业界的观点。
Int J Parasitol. 2010 Aug 15;40(10):1177-81. doi: 10.1016/j.ijpara.2010.04.005. Epub 2010 Apr 27.
5
The right to a trial: Should dying patients have access to experimental drugs?审判权：临终患者是否应有权使用实验性药物？
New Yorker. 2006 Dec 18:40-7.
6
The antibiotic pipeline--challenges, costs, and values.抗生素研发进程——挑战、成本与价值
N Engl J Med. 2004 Aug 5;351(6):523-6. doi: 10.1056/NEJMp048093.
7
Bioequivalence: the regulatory career of a pharmaceutical concept.生物等效性：一个药学概念的监管历程。
Bull Hist Med. 2011 Spring;85(1):93-131. doi: 10.1353/bhm.2011.0024.
8
Direct-to-consumer prescription drug advertising: history, regulation, and issues.直接面向消费者的处方药广告：历史、监管及问题
Minn Med. 2010 Mar;93(3):50-2.
9
Antibacterial drug discovery in the 21st century.21世纪的抗菌药物发现
Clin Microbiol Infect. 2004 Nov;10 Suppl 4:10-7. doi: 10.1111/j.1465-0691.2004.1005.x.
10
Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future.药品监管环境下的生物制药统计学：过去、现在与未来。
J Biopharm Stat. 2001 Nov;11(4):347-72.
引用本文的文献
1
The promise of molecular science in brain health. What breakthroughs are anticipated in the next 20 years?分子科学在脑健康领域的前景。未来20年有望取得哪些突破？
Cereb Circ Cogn Behav. 2024 Aug 22;7:100364. doi: 10.1016/j.cccb.2024.100364. eCollection 2024.
2
Antileishmanial Drug Discovery and Development: Time to Reset the Model?抗利什曼原虫药物的发现与开发：是时候重置模式了吗？
Microorganisms. 2021 Dec 2;9(12):2500. doi: 10.3390/microorganisms9122500.
3
Pharmacokinetic Analysis of Epithelial/Endothelial Cell Barriers in Microfluidic Bilayer Devices with an Air-Liquid Interface.具有气液界面的微流控双层装置中上皮/内皮细胞屏障的药代动力学分析
Micromachines (Basel). 2020 May 25;11(5):536. doi: 10.3390/mi11050536.
4
A Bayesian machine learning approach for drug target identification using diverse data types.基于多种数据类型的药物靶点识别的贝叶斯机器学习方法。
Nat Commun. 2019 Nov 19;10(1):5221. doi: 10.1038/s41467-019-12928-6.
5
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.继发进展型多发性硬化症的药物治疗：概述。
CNS Drugs. 2018 Jun;32(6):499-526. doi: 10.1007/s40263-018-0538-0.
6
Eminence or Evidence? The Volatility, Uncertainty, Complexity, and Ambiguity in Healthcare.卓越还是证据？医疗保健中的波动性、不确定性、复杂性和模糊性。
J Pharmacol Pharmacother. 2017 Jan-Mar;8(1):1-2. doi: 10.4103/jpp.JPP_12_17.
7
Creativity in large pharmaceutical research organizations: unleash the hungry drug hunter.大型制药研究机构中的创造力：释放饥饿的药物猎手。
Br J Pharmacol. 2017 Jul;174(13):2152-2153. doi: 10.1111/bph.13775. Epub 2017 Apr 3.
8
"Omics"-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives.“组学”助力的药物与生物标志物发现：机遇、挑战与未来展望
Proteomes. 2016 Sep 12;4(3):28. doi: 10.3390/proteomes4030028.
9
The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses.冗余、误导性及存在冲突的系统评价和Meta分析的大量产出。
Milbank Q. 2016 Sep;94(3):485-514. doi: 10.1111/1468-0009.12210.
10
Emerging applications of metabolomics in drug discovery and precision medicine.代谢组学在药物发现和精准医学中的新兴应用。
Nat Rev Drug Discov. 2016 Jul;15(7):473-84. doi: 10.1038/nrd.2016.32. Epub 2016 Mar 11.
本文引用的文献
1
A proposal for radical changes in the drug-approval process.一项关于药物审批流程彻底变革的提议。
N Engl J Med. 2006 Aug 10;355(6):618-23. doi: 10.1056/NEJMsb055203.
2
Circumventing resistance to kinase-inhibitor therapy.规避对激酶抑制剂疗法的耐药性。
N Engl J Med. 2006 Jun 15;354(24):2594-6. doi: 10.1056/NEJMe068073.
3
The NIH budget and the future of biomedical research.美国国立卫生研究院的预算与生物医学研究的未来。
N Engl J Med. 2006 Apr 20;354(16):1665-7. doi: 10.1056/NEJMp068050.
4
FDA centennial.美国食品药品监督管理局成立一百周年。
Science. 2006 Apr 7;312(5770):19. doi: 10.1126/science.1127486.
5
Rescuing the NIH before it is too late.趁为时未晚拯救美国国立卫生研究院。
J Clin Invest. 2006 Apr;116(4):844. doi: 10.1172/JCI28364.
6
Biomedical research. A cure for medicine's ailments?
Science. 2006 Mar 31;311(5769):1852-4. doi: 10.1126/science.311.5769.1852.
7
FDA standards--good enough for government work?美国食品药品监督管理局的标准——对政府工作来说足够好了吗？
N Engl J Med. 2005 Sep 8;353(10):969-72. doi: 10.1056/NEJMp058174.
8
Productivity counts--but the definition is key.生产力很重要——但定义是关键。
Science. 2005 Jul 29;309(5735):726. doi: 10.1126/science.309.5735.726.
9
What ails the FDA?美国食品药品监督管理局怎么了？
N Engl J Med. 2005 Mar 17;352(11):1063-6. doi: 10.1056/NEJMp058003.
10
FDA publishes analysis of the pipeline problem.
Nat Rev Drug Discov. 2004 May;3(5):379. doi: 10.1038/nrd1404.
Zotero 插件